Aktie A2DG49 KALVISTA PHARMACEUTICALS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen KalVista Pharmaceuticals, Inc.

Aktien

A2DG49

US4834971032

KALV

Markt geschlossen - Nasdaq
Andere Börsenplätze
 22:00:00 27.06.2024 		% 5 Tage % 1. Jan.
12,05 USD +6,54 % Intraday Chart für KalVista Pharmaceuticals, Inc. +7,49 % -1,63 %
27.06. KalVista startet Studie zum hereditären Angioödem bei pädiatrischen Patienten MT
27.06. KalVista Pharmaceuticals, Inc. Start der KONFident-KID-Studie zur bedarfsgerechten Behandlung von hereditären Angioödem-Attacken mit Sebetralstat bei Kindern im Alter von 2 bis 11 Jahren CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
KalVista Starts Hereditary Angioedema Trial in Pediatric Patients
KalVista Pharmaceuticals : Corporate Presentation June 2024
KalVista Initiates KONFIDENT-KID Trial for On-demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Children Aged 2 to 11
KalVista Pharmaceuticals, Inc. Initiates KONFident-KID Trial for On-Demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Children Aged 2 to 11
KalVista Pharmaceuticals Submits New Drug Application to FDA for Investigational Hereditary Angioedema Treatment
KalVista Seeks FDA OK of Sebetralstat for Hereditary-Angioedema Attacks
KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for Hereditary Angioedema
KalVista Pharmaceuticals, Inc. Submits New Drug Application to FDA for Sebetralstat as First Oral On-Demand Treatment for Hereditary Angioedema
KalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024
KalVista Pharmaceuticals, Inc. Presents Data At Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024
KalVista Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KalVista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024
Kalvista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema At the European Academy of Allergy and Clinical Immunology Congress 2024
Sector Update: Health Care Stocks Higher Late Afternoon
Sector Update: Health Care
KalVista Prospective Treatment for Swelling Disorder Meets Objectives -- Shares Rise
Kalvista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating Its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema
KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema
KalVista Pharmaceuticals Announces Ten Abstracts Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2DG49 Aktie
  4. Nachrichten KalVista Pharmaceuticals, Inc.
  5. Andere Sprachen